Thursday, March 11, 2010
"Concise industry news from the US pharmaceutical industry..."
Sponsors
Platinum Sponsors
Nanopoint, Inc.
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
Gold Sponsors
Waters Corp.
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
Silver Sponsors
Platinum Sponsors
Nanopoint, Inc.
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
Gold Sponsors
Waters Corp.
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
Silver Sponsors
Blog
Where our team of editors discuss what they think about the current NGP US Issues.
Marie Shields
Editor NGP US
Editor NGP US
Sizing up the future
What role will individually tailored therapies play in the pharmaceutical industry’s new business models?01 Oct 2009
Focus Areas
Cover Stories
Creating an Oncology Powerhouse
Millennium Pharmaceuticals CEO Deborah Dunsire talks about the company’s innovative pipeline, the hopes for its market-leading cancer product...
On the Cutting Edge
Corey Goodman of Pfizer talks about his role in translating biomedical discoveries into new medicines.
Putting the Pieces Together
The mission of MIT’s MEHD Group is to envision the future of the healthcare system and create new knowledge, new technologies and new business...
Vendor Perspectives
-
Clinical Operations Process Automation –...
Why clinical operations? Over the last 2 decades there has been a great deal of work by pharmaceutical and biotechnology companies and their software vendors to provide...Read more -
Choosing a Bioanalytical Lab 101: Beyond...
Broaden your horizons with these five critical service elements. By Mickey O’Brien, PK/PD Specialist, Eurofins MedinetRead more
Industry Analysts
-
Tools of the Trade
McKinley Scientific was formed to provide a boutique market approach to a large industry. Our goal is to make the acquisition and disposition of scientific instrumentation...Read more -
Increasing Throughput in the Drug Discover...
Like many companies in today’s environment, pharmaceutical companies must improve their bottom line results in increasingly difficult circumstances. By Grace DivisionRead more -
Providing Better Tools, Better Research an...
Multiplexed gene expression assays benefit research and diagnostics by addressing the multi-factorial nature of many disease and drug mechanisms. By High Throughput...Read more -
Going Green
Call it green, call it sustainability, but being environmentally savvy is not a trend. It’s an important business practice that’s here to stay, as Nikki Nicholson of the...Read more
Executive Interviews
High Profiling
John Kozarich of ActivX Biosciences updates NGP on the development of KiNativ, a proprietary platform for High-Content Kinase Profiling, and its impact on the future of kinase inhibitor discovery.
Read more
Put to the Test
Robert Willis from Eurofins Medinet gives an overview of developments at the company.
Read more
Next Generation Healthcare Summit 2010
11th - 13th May
As healthcare costs continue to rise, health providers around the country feel a sharp sense of urgency in deploying information technology to lower costs, reduce medical errors, enhance outcomes, and spur efficiency in an industry known for legendary inefficiency.
Source: www.ngpharma.com© 2010 GDS Publishing Ltd. All rights reserved.